52 Week Range
As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Chongqing Zhifei Biological Products' Q3 Net Profit Up 58.1% Y/Y
Shenzhen Exchange Filing Shows Block Trade Of Zhifei Biological Products' Shares Involving 507.4 Mln Yuan
Shenzhen Exchange Filing Shows Block Trade Of Chongqing Zhifei Biological Products' Shares Involving 455 Mln Yuan
Chongqing Zhifei Biological Products Co., Ltd. is a China-based company principally engaged in the research, development, production, sale and distribution of vaccine products. The Company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevision and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus and other virus, general drugs and other biological products, among others. The Company is also involved in the agency sale of vaccines. The Company distributes its products in domestic market and to overseas markets, with Central China as its main market.
Biotechnology & Drugs
No. 7, Jinyuan Road, Jiangbei District
Chairman of the Board, General Manager
Vice Chairman of the Board, Deputy General Manager
Chief Financial Officer, Deputy General Manager, Director
Deputy General Manager
Deputy General Manager
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
(Adds IDT Biologika; updates AstraZeneca, Russia vaccine, Johnson & Johnson) Oct 14 (Reuters) - More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 42 in human trials, according to the World Health Organization (WHO...
More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...
0221GMT - * 中国医药股股价大幅下跌，沪深医药卫生指数一度下滑3.3%--有可能连续第三天收低 * 尽管周一下跌，但该指数今年以来仍上涨逾50%，涨幅名列前茅，因投资者在新冠疫情期间追捧医药股 * 国信证券分析师在报告中称，由于估值过高，医药股面临修正风险 * 复星医药领跌，一度下跌7%，上周五下挫8%；其在香港上市的股票也跌3.1% * 沃森生物、智飞生物、华兰生物、康泰生物和康弘药业 下跌5.5-7%不等 (完) (编译 郑茵 审校 艾茂林)
(Updates Johnson & Johnson; adds Cadila Healthcare Ltd, University of Queensland) July 17 (Reuters) - More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, which has killed hundreds of thousands and ravaged the global economy...
China minted three times as many new billionaires than the United States in the past year, with fortunes made in drugs and online entertainment after a mini-boom from the coronavirus outbreak, a ranking of the world's wealthiest people shows.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.